Board of Advisors
R.J. Sims Preston, JD
R.J. Sims Preston, JD was the Chairman and President of Polyglot Systems, Inc. from November 2010 to March 2017 when the company was sold to a strategic buyer, securing a substantial return for shareholders.
Prior to joining Polyglot, Sims spent 14 years as a lawyer, both in private practice and as in-house counsel for some of the world’s most dynamic and innovative companies, including Quintiles Transnational Corp. (now IQVIA) and Nuance Communications, Inc.
In addition to his executive experience, Sims’ legal work has involved software licensing, strategic transactions, intellectual property prosecution and maintenance and litigation. Mr. Preston earned a BA from Columbia University and is a cum laude graduate of Duke University School of Law.
Julius M. Wilder MD, PHD
Dr. Julius Wilder obtained the first MD, PhD in Medical Sociology in the history of Duke University. Following medical school and graduate school he completed a residency in internal medicine at Duke where he served as an Assistant Chief Resident. At the end of his residency, Dr. Wilder completed a fellowship in gastroenterology and an advanced transplant hepatology fellowship at Duke. He is an Assistant Professor of Medicine and has a tenure-track faculty appointment in the Duke School of Medicine, the Duke Clinical Research Institute, and the Duke Department of Sociology (secondary appointment). He serves on the Duke School of Medicine executive admissions committee, Duke School of Medicine institutional review committee, and is the Diversity Chair for the Duke Division of Gastroenterology.
Dr. Wilder has numerous publications and has won awards for his research in hepatology, GI, and on social determinants of health. He is the Principal Investigator (PI) or Co-PI on multiple clinical trials in gastroenterology, hepatology and transplant hepatology. His clinical duties include working as a gastroenterologist/hepatologist at Duke University and Duke Regional Hospitals in Durham, North Carolina.
Karin Jorga, PhD
Dr. Karin Jorga, PhD, has over 20 years of experience in drug development of small and large molecules across all therapeutic areas. The focus of her international experience has been on transitioning pre-clinical lead molecules to Clinical Proof-of-Concept and advancing novel biomarkers to drive Personalized Healthcare. She has a substantial scientific track record in Clinical Pharmacology and a unique set of expertise that includes the usage of Biomarkers and application of Computer Models to overcome drug development hurdles and drive scientifically sound decision making.
Dr. Jorga’s past experience includes being the Global Head of Biomarker Technology and Science, Global Head of Clinical Pharmacology, and Global Head of Modeling and Simulation at Roche.
She currently runs a consulting firm, KarinJorga Life Science Consulting, that was founded in 2014 in Basel with the ambition to develop scientific innovations into medicines for tomorrow.
Kelly W Padilla, BSPharm PharmD
Dr. Padilla is a clinical pharmacist of over 20 years who has served in many clinical leadership roles within the pharmaceutical industry: global clinical supplies, regulatory affairs regulatory intelligence, medical writing, global medical affairs, medical communications, and hospital pharmacy.
She has been the global medical information lead for several product launches and has been a functional head in several pivotal trials in respiratory, oncology, HIV, CNS, urology, and orthopedics; for both small molecules and biologics. Kelly holds a Doctor of Pharmacy from the University of Florida, and a Bachelor of Science of Pharmacy from the University of North Carolina – Chapel Hill.
Dr. Padilla is also a graduate of the prestigious NC School of Science and Mathematics.
Personal: Outside of work, Kelly plays the flute and dances salsa. She enjoys traveling and cuddling with her 2 daughters and fur-baby Naomi the poodle.
Bimal Shah, MD, MBA
Dr. Bimal Shah is currently the Chief Medical Officer at Livongo (NASDAQ: LVGO).
Dr. Shah is responsible for Livongo’s strategic clinical product vision, clinical content, and clinical research and analytics. Dr. Shah previously served as the company’s Senior Vice President for Clinical and Strategic Partnerships, where he provided clinical guidance and launched Livongo first cardiovascular product offering, assisted in strategic pursuits, and explored opportunities to expand Livongo’s offerings into other parts of the healthcare market. Prior to Livongo, Dr. Shah was the Service Line Vice President at Premier, Inc for its real-world evidence business.
Prior to Premier, Dr. Shah served as an Assistant Professor at Duke University, where he held numerous leadership positions in research programs and clinical administration. Dr. Shah graduated from the University of North Carolina – Chapel Hill with the highest honors and earned both a Doctor of Medicine and Masters in Business Administration from Duke University. Dr. Shah completed his residency in Internal Medicine at Stanford University before finishing a General Cardiology fellowship at Duke University. He is also a member of both the Board of Advisors for the Duke School of Nursing and Board of Visitors for the University of North Carolina – Chapel Hill. Dr. Shah is a practicing cardiologist.
Dr. Shah is also a graduate of the prestigious NC School of Science and Mathematics.
Richard A. Graham, Ph.D., was appointed Senior Vice President, Development in August 2020, where he is responsible for leading the progression of late-stage clinical assets through regulatory filing and approval. Since joining Theravance Biopharma, Dr. Graham has served as Vice President of Clinical Pharmacology, and more recently, as Vice President of Clinical Development.
Prior to joining Theravance Biopharma, Dr. Graham spent five years at GlaxoSmithKline working in the area of Drug Metabolism and Pharmacokinetics, seven years at Genentech/Roche as a clinical pharmacologist and Global Development Team Leader, and one year at Onyx Pharmaceuticals where he headed Translational Medicine. In his nearly 20-year career, he worked across all stages of drug development and all major therapeutic areas.
Dr. Graham received his Bachelor’s and Master’s degree in Biochemistry from Iowa State University and his Doctorate of Philosophy degree in Pharmaceutical Sciences from The University of North Carolina at Chapel Hill.
TruLab’s board of advisors possesses a collective 126 years experience in the pharmacological and medical fields.
This experience of our board is invaluable to the executive team and influences every decision we make as a company.